Lilly raises 2025 guidance on strong 3rd-qtr results

30 October 2025

US pharma major Eli Lilly (NYSE: LLY) today announced its financial results for the third-quarter of 2025, exceeding expectations and pushing its share price up 7% in pre-market activity.

Worldwide revenue for the quarter was $17.60 billion, an increase of 54% compared with third quarter 2024, driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices. This surpassed the analyst consensus estimate of $16.01 billion, according to data provided by LSEG. Key Products revenue grew to $11.98 billion, led by Mounjaro and Zepbound, both based on tirzepatide.

Net income and earnings per share (EPS) were $5.58 billion and $6.21, respectively, compared with net income of $970.3 million and EPS of $1.07 in Q3 2024.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK